Endothelin 1

Vasoconstricting peptide From Wikipedia, the free encyclopedia

Endothelin 1 (ET-1), also known as preproendothelin-1 (PPET1), is the most potent vasoconstrictor produced by the human body.[5] It is a peptide produced by vascular endothelial cells,[6] as well as by cells in the heart (affecting contractility) and kidney (affecting sodium handling).[7] The protein encoded by this gene EDN1 is proteolytically processed to release endothelin 1. Endothelin 1 is one of three isoforms of human endothelin.

PDBOrtholog search: PDBe RCSB
AliasesEDN1, ARCND3, ET1, HDLCQ7, QME, endothelin 1, PPET1
Quick facts EDN1, Available structures ...
EDN1
Available structures
PDBOrtholog search: PDBe RCSB
Identifiers
AliasesEDN1, ARCND3, ET1, HDLCQ7, QME, endothelin 1, PPET1
External IDsMGI: 95283; HomoloGene: 1476; GeneCards: EDN1; OMA:EDN1 - orthologs
Orthologs
SpeciesHumanMouse
Entrez
Ensembl
UniProt
RefSeq (mRNA)

NM_001168319
NM_001955

NM_010104

RefSeq (protein)

NP_001161791
NP_001946
NP_001161791
NP_001946

NP_034234

Location (UCSC)Chr 6: 12.29 – 12.3 MbChr 13: 42.45 – 42.46 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse
Close

Sources

Preproendothelin is precursor of the peptide ET-1. Endothelial cells convert preproendothelin to proendothelin and subsequently to mature endothelin, which the cells release.[6][8]

Clinical significance

Patients with salt-sensitive hypertension have higher plasma ET-1.[7] Endothelin-1 receptor antagonists (Bosentan) are used in the treatment of pulmonary hypertension.[6] Use of these antagonists prevents pulmonary arterial constriction and thus inhibits pulmonary hypertension.[6]

As of 2020, the role of endothelin-1 in affecting lipid metabolism and insulin resistance in obesity mechanisms was under clinical research.[9]

References

Related Articles

Wikiwand AI